Failure of B7.1-modified tumor to evoke full activation of CD8+ tumor-infiltrating lymphocytes in the central nervous system: prevention of parental tumor growth in the subcutaneous environment.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of Neurosurgery

• Publication date

  2002-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3171/JNS.2002.97.2.0432PMID 12186473
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anti-tumor gene therapy

  2004cited by this paper
• PD-L2 is a second ligand for PD-1 and inhibits T cell activation

  2001cited by this paper
• Postoperative immuno-gene therapy of murine bladder tumor by in vivo administration of retroviruses expressing mouse interferon-γ

  2001cited by this paper
• The expanding B7 superfamily: Increasing complexity in costimulatory signals regulating T cell function

  2001cited by this paper
• CD8+ Tumor-Infiltrating Lymphocytes Are Primed for Fas-Mediated Activation-Induced Cell Death But Are Not Apoptotic In Situ1

  2001cited by this paper
• B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production.

  2001cited by this paper
• B7-H3: A costimulatory molecule for T cell activation and IFN-γ production

  2001cited by this paper
• Gene therapy for brain tumors

  2000cited by this paper
• Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

  2000cited by this paper
• B7.1 expression by the weakly immunogenic F98 rat glioma does not enhance immunogenicity

  2000cited by this paper
• Gene transfer of a secretable form of IL‐15 in murine adenocarcinoma cells: Effects on tumorigenicity, metastatic potential and immune response

  2000cited by this paper
• The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status

  2000cited by this paper
• Characterization of a new human B7-related protein: B7RP-1 is the ligand to the co-stimulatory protein ICOS.

  2000cited by this paper
• Characterization of Human Inducible Costimulator Ligand Expression and Function1

  2000cited by this paper
• T-cell co-stimulation through B7RP-1 and ICOS

  1999cited by this paper
• Induction of effective antitumor immunity in a mouse brain tumor model using B7‐1 (CD80) and intercellular adhesive molecule 1 (ICAM‐1; CD54) transfection and recombinant interleukin 12

  1999cited by this paper
• Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2.

  1999cited by this paper
• The central effectors of cell death in the immune system.

  1999cited by this paper
• Regression of intracerebral rat glioma isografts by therapeutic subcutaneous immunization with interferon-γ, interleukin-7, or B7-1-transfected tumor cells

  1999cited by this paper
• Tumor antigen presentation: changing the rules

  1998cited by this paper
• Co-stimulation in T cell responses.

  1997cited by this paper
• Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation.

  1997cited by this paper
• Adoptive transfer of cytotoxic T lymphocytes induced by CD86-transfected tumor cells suppresses multi-organ metastases of C1300 neuroblastoma in mice

  1997cited by this paper
• Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.

  1996cited by this paper
• Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo?

  1996cited by this paper
• CD28/B7 system of T cell costimulation.

  1996cited by this paper
• A reassessment of the role of B7-1 expression in tumor rejection

  1995cited by this paper
• Unraveling Immune Privilege

  1995cited by this paper
• A role for CD95 ligand in preventing graft rejection

  1995cited by this paper
• Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules.

  1995cited by this paper
• B7-1 and interleukin 12 synergistically induce effective antitumor immunity.

  1995cited by this paper
• CD28 and apoptosis.

  1995cited by this paper
• Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules.

  1994cited by this paper
• Autoimmunity in the eye and its regulation.

  1994cited by this paper
• Generation of cytotoxic immune responses during the progression of a rat glioma.

  1994cited by this paper
• Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice.

  1993cited by this paper
• Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.

  1993cited by this paper
• The role of the CD28 receptor during T cell responses to antigen.

  1993cited by this paper
• Studies on the induction of anterior chamber‐associated immune deviation (ACAID) III. Induction of ACAID depends upon intraocular transforming growth factor‐β

  1992cited by this paper
• Adoptive immunotherapy of intracerebral metastases in mice.

  1990cited by this paper
• B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid cell lines, and Burkitt's lymphomas.

  1982cited by this paper
• Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye.

  1948cited by this paper

• Immunomodulatory Effects of Hemagglutinin- (HA-) Modified A20 B-Cell Lymphoma Expanded as a Brain Tumor on Adoptively Transferred HA-Specific CD4+ T Cells

  2014cites this paper
• Mouse models of primary central nervous system lymphomas: tools for basing funding and therapeutic strategies

  2014cites this paper
• Preoperative radiotherapy contributes to induction of proliferative activity of CD8+ tumor-infiltrating T-cells in oral squamous cell carcinoma.

  2006cites this paper